Successful trials of IDH-inhibitors for IDH-mutant astrocytoma, BRAF inhibitors for BRAF-mutant glioma, and MEK inhibitors for pediatric low-grade glioma have demonstrated the potential impact of targeted therapy for gliomas, but unfortunately not yet in GBM [4–6]. This evidence concerns the gene MAP2K7 and glioma.